Browse studies

Find your next paid study

7 recruiting studies matching your filters

A Phase 1 Study of AUTX-703 in Participants With Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharm…

Relapsed Acute Myeloid Leukemia (AML)Refractory Acute Myeloid Leukemia (AML)Relapsed/Refractory AML+3 more

Estimated

~$10 – $8,750

Auron Therapeutics, Inc.NCT06846606

Phase 2

Pilot Single Arm Phase 2 Study of Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

This is a prospective, single-arm phase 2 pilot study to assess the response rate of IDH1 mutated relapsed/refractory acute myeloid leukemia (AML) patients who…

IDH1 MutationRelapsed / Refractory AML

Estimated

~$10 – $7,500

Timothy PardeeNCT07471841

Phase 2

Metronomic Decitabine-Cedazuridine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia R/R AML), High Risk Myelodysplastic Syndrome (HR-MDS), and High-Risk Myeloproliferative Neoplasms (HR/AP MPN)

This is a single-center randomized phase 2 open-label clinical trial.

Relapsed / Refractory AMLHigh Risk Myelodysplastic SyndromeHigh Risk Myeloproliferative Neoplasms

Estimated

~$10 – $6,250

Virginia Commonwealth UniversityNCT07710534

Phase 1

Safety and Efficacy of Expanded KIR-HLA Mismatched Natural Killer Cell Immunotherapy (AdaptNK) for High-Risk Myeloid Diseases as Bridge to Allogeneic Hematopoietic Stem Cell Transplantation

This is a multi-institutional Phase I/II study of an allogeneic KIR-HLA mismatched NK cell infusion (AdaptNK) and a short course of subcutaneous interleukin-2 …

Relapsed Adult AMLRefractory AMLAcute Myelogenous Leukemia

Estimated

~$10 – $6,250

Masonic Cancer Center, University of MinnesotaNCT07591649

Phase 1

A Phase I/II Clinical Trial Evaluating the Safety and Efficacy of Universal Donor CD33 CAR Natural Killer Cells for Treatment of Relapsed/Refractory Acute Myeloid Leukemia

This phase 1/2 study is testing a new treatment for acute myeloid leukemia (AML) that has come back or has not responded to other treatments. The treatment use…

Relapsed/Refractory AML

Estimated

~$10 – $6,250

Nationwide Children's HospitalNCT07026942

Phase 1

Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination With Ziftomenib or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib for the Treatment of Patients With Acute Myeloid Leukemia

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This pr…

Acute Myeloid LeukemiaMixed Lineage Leukemia Gene MutationRefractory AML+7 more

Estimated

~$10 – $8,750

Kura Oncology, Inc.NCT05735184

Phase 1

A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed …

Leukemia, Myeloid, AcuteRefractory AMLRelapsed Adult AML+2 more

Estimated

~$10 – $8,750

Aptose Biosciences Inc.NCT03850574